Meeder Asset Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Meeder Asset Management’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-260	Closed	-$7K	–	2212
2019 Q1	$7K	Buy	260 +6	+2%	+$153	﹤0.01%	1340
2018 Q4	$6K	Buy	254 +132	+108%	+$5.16K	﹤0.01%	1388
2018 Q3	$7K	Buy	+122	New	+$7.79K	﹤0.01%	1267
2018 Q2	–	Sell	-21	Closed	-$1K	–	1742
2018 Q1	$1K	Buy	+21	New	+$1.84K	﹤0.01%	1515
2017 Q2	–	Sell	-18	Closed	-$3K	–	2000
2017 Q1	$3K	Sell	18 -297	-94%	-$33.3K	﹤0.01%	1311
2016 Q4	$25K	Buy	+315	New	+$24.9K	﹤0.01%	626

Other funds holding TTPH

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Meeder Asset Management's TTPH Position: Q2 2019 in Review

Meeder Asset Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q2 2019, closing a stake of 260 shares — an estimated $7K sold.

Meeder Asset Management first reported a position in TTPH in Q4 2016 and held it in 6 quarters. The position peaked at $25K in Q4 2016. 66 funds tracked by Wall St. Rank hold TTPH as of Q2 2019.

Meeder Asset Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Meeder Asset Management sold 260 Tetraphase Pharmaceuticals, Inc. shares in Q2 2019, an estimated $7K.
Meeder Asset Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2016 and held it in 6 quarters.
Meeder Asset Management's Tetraphase Pharmaceuticals, Inc. position peaked at $25K in Q4 2016.
66 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q2 2019.

Based on Meeder Asset Management's 13F filing for Q2 2019, filed 5 Aug 2019.